ZIOPHARM (ZIOP) Gets Nod from IDMC to Continue Palifosfamide PICASSO 3
Up)
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), reports that the Independent Data Monitoring Committee (IDMC) has unanimously recommended continuation of the international, randomized, double-blinded, placebo-controlled Phase 3 trial (PICASSO 3) of palifosfamide (Zymafos or ZIO-201) in front-line metastatic soft tissue sarcoma.
The IDMC reviewed all available study data and determined that the trial should continue as designed and conducted, which is the third such review and recommendation by the committee. Targeted completion of enrollment for PICASSO 3 is expected by the end of the first quarter of 2012. The outcome in progression-free survival, the study's primary endpoint for accelerated approval, is anticipated in the second half of 2012.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The IDMC reviewed all available study data and determined that the trial should continue as designed and conducted, which is the third such review and recommendation by the committee. Targeted completion of enrollment for PICASSO 3 is expected by the end of the first quarter of 2012. The outcome in progression-free survival, the study's primary endpoint for accelerated approval, is anticipated in the second half of 2012.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- HeartWare (HTWR) Publishes Encouraging Data from ADVANCE in Advanced Heart Failure
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
